Inflammatory Bowel Disease

Add Content

• Definition
• Introduction
• Signs & Symptoms
• Research Summary

Presentation Slides

---

Executive Summary

---

Write an executive summary in the form of a blog article on the topic of "Research into Chinese medicine treatment for Inflammatory Bowel Disease" summarising the research below and using language that can be easily understood by patients and avoiding medical jargon using a professional and caring tone of voice.

Write an executive summary in the form of a blog article on the topic of "Researched Chinese medicine treatments for Inflammatory Bowel Disease" summarising the research below in an objective and easy to understand way, and using language that can be easily understood by patients. Group the article into Chinese medicine treatments first, followed by nutrition and other treatments. Avoid using medical jargon and use a professional and caring tone of voice.

Write me a concise but easy to understand executive summary on the topic of "Chinese medicine treatments for Inflammatory Bowel Disease" based on the following research that I will give you. Your summary should be 2 paragraphs long in Australian English spelling and include references to the studies.

A Systematic Review published in 2024 in the journal Heliyon found that Acupuncture and moxibustion therapies have shown effectiveness in treating ulcerative colitis according to the summarised-findings of various systematic reviews and meta-analyses. Methodology: This evaluative study used an extensive and systematic methods to search data from seven different databases. The selected data were further refined by using different screening and evaluation frameworks like AMSTAR-2, PRISMA, ROBIS, and GRADE systems. These were used to determine the methodological quality, reporting quality, risk of bias, and the quality of evidence in the selected studies. Discussion of results: After critical evaluation, the study found ten relevant reviews and analyses that showed potential for acupuncture and moxibustion therapies being effective in ulcerative colitis treatment. However, many the identified studies were reported to have several problems in their overall design and quality of outcomes. The researchers therefore stress caution when interpreting these results due to the lack of high-quality evidence in the existing studies.

A Theoretical Article published in 2023 in the journal Frontiers in Pharmacology found that Traditional Chinese medicine has been found to effectively treat ulcerative colitis by repairing various components of the damaged intestinal mucosal barrier. In the methodology, the study sought to uncover the efficacy of Traditional Chinese medicine (TCM) in treating ulcerative colitis (UC). The research began by acknowledging the key role that damage to the intestinal mucosal barrier plays in the development of UC. It then explored how TCM could combat UC by protecting and repairing various aspects of this barrier including the physical, chemical, immune, and biological barrier. In the results discussion, it was discovered that TCM not only increases the number of intestinal epithelial cells, tight junction proteins, and mucins, but also encourages the proliferation of intestinal stem cells, restores the abundance of the intestinal microbiota, and modulates immunity in the gut. Moreover, the study identified several upstream proteins and signaling pathways that were activated in the process. This gives hope to future treatment plans for UC using TCM, with the study providing a fundamental theoretical basis and new ideas for future investigations.

A Meta-Analysis published in 2023 in the journal Journal of Pharmacopuncture found that Acupuncture combined with moxibustion has shown significant benefits in the treatment of mild to moderate Crohn's disease. In this systematic review, the researchers conducted a comprehensive search of 12 databases for randomized controlled trials on the impact of acupuncture on Crohn's disease. Three independent reviewers assessed the risk of bias for each study. The level of evidence from meta-analyses was evaluated using the Grading of Recommendations, Assessment, Development, and Evaluation methodology. The review included a total of 12 studies. Findings suggest that acupuncture combined with moxibustion, a traditional East Asian treatment involving burning a small bunch of herbs on particular points on the body, had an effect on the treatment outcomes for patients with mild to moderate Crohn's disease when compared to a group given sham acupuncture and sham moxibustion treatments. Notably, findings on the effectiveness of acupuncture treatment only, without the addition of moxibustion, were less clear. It is also important to emphasize that this review was firmly focused on the benefits of the treatment on patients with mild to moderate symptoms of Crohn's disease.

A Meta-Analysis published in 2023 in the journal Medicine found that Acupoint application has been proven to be a safe and effective method for the treatment of ulcerative colitis. The methodology incorporated a systematic review of various databases including China National Knowledge Infrastructure, Chinese Biology Medicine, VIP, Wanfang, Embase, PubMed, the Cochrane Library and Web of Science up to July 2022 to find published randomized controlled trials on the use of acupoint application in treating ulcerative colitis. Meta-analysis and trial sequential analysis were then performed on the selected studies. The results from the 13 analyzed trials involving a total of 878 cases revealed that the use of acupoint application improved the rates of effective clinical comprehensive and syndrome in ulcerative colitis treatment compared to conventional western medicine. The method also showed advantages in increasing interleukin-4 and reducing interferon-gamma. Also noted was that there were no variances seen regarding colonoscopy, pathological examination, and reaction rates when compared with traditional methods. The quality of the evidence used for these conclusions varied, with some being of moderate quality and others deemed low or very low quality.

A Meta-Analysis published in 2023 in the journal Complementary Therapies in Medicine found that Acupuncture demonstrates a positive therapeutic effect on inflammatory bowel disease (IBD) by effectively regulating associated inflammatory factors. Eight electronic databases were utilized in a systematic search for studies that satisfied the pre-defined inclusion parameters. Two impartial reviewers evaluated the quality of the resultant studies and a meta-analysis was then performed to assess the efficacy of acupuncture on IBD and its related inflammatory factors which include TNF-α, IL-1, IL-8, and IL-10. The analysis comprised of four randomized controlled trials that involved a total of 228 patients. The beneficial effects of acupuncture on IBD patients were thoroughly inspected, as well as its ability to regulate levels of specified inflammatory factors. The P values, which refer to the probability that any observed result occurred by chance, were critically assessed for every inflammatory factor - significance was found in the values of TNF-α, IL-8, and IL-10, but not for IL-1. The conclusion drawn was that acupuncture has a positive therapeutic impact on individuals suffering from IBD, and quite importantly, can regulate inflammatory factors in these patients. As a result of these findings, it is suggested that TNF-α, IL-8, and IL-10 are the ideal inflammatory indicators for evaluating the anti-inflammatory response in this patient category.

A Review Article published in 2022 in the journal Phytomedicine found that Chinese Herbal Medicine Prescriptions (CHMPs) have demonstrated to be potentially effective in managing Inflammatory Bowel Disease (IBD) with a comprehensive, holistic approach. In their methodology, the authors reviewed both preclinical and clinical researches to evaluate the effectiveness of CHMPs in treating IBD. They performed screenings of articles that highlighted the use of CHMP as a treatment option for IBD, giving them an insight into the complexity of the disease and the sophistication of CHMP treatments. Subsequently, they conducted an umbrella review of multiple meta-analyses linked to CHMPs to comprehend the efficacy of these herbal prescriptions in a clinical setting; they narrowed down from 1174 records to 12 substantial references for the review. In discussing their results, the authors analyzed a variety of 14 CHMPs that have a historical usage background and discussed their respective mechanisms of action. They delve into the inherent characteristics of the herbs used to provide a comprehensive understanding of the CHMPs. Recognizing the holistic nature being integral to CHMP, the authors discussed how the implementation of omics, studying the gut microbiome, and network pharmacology can enhance the understanding of CHMPs' bioactions in treating IBD.

A Cohort Study published in 2022 in the journal Journal of Ethnopharmacology found that Shenling Baizhu San (SBS), combined with mesalamine, can treat ulcerative colitis effectively by changing gut microbiota structures and increasing tryptophan metabolite levels. The methodology involved conducting a prospective cohort study to explore the potential therapeutic effects of SBS, used as a complementary medicine with mesalamine, on ulcerative colitis patients. There were 48 patients included in the study, out of which 24 were a part of the control group and given just mesalamine, while the remaining patients in the experimental group were administered mesalamine along with SBS. The efficacy of these treatments was evaluated after an elapsed period of 8 weeks. The study utilized procedures like 16S rRNA sequencing to observe the structures of gut microbiota (GMB), and UPLC-MS/MS to analyze microbial tryptophan metabolites. In terms of results discussion, the study noticed that the combination of SBS and mesalamine significantly enhanced the clinical symptoms of ulcerative colitis. This was observed through mucosal healing and reduced damage to the colon that the medicinal combination induced. The research also highlighted a novel discovery, the alteration of gut microbiota structures, and an observable increase in microbial levels of tryptophan metabolites when both SBS and mesalamine were used. This led to the conclusion that SBS acted as an effective supplementary therapy to the standard treatment, easing ulcerative colitis through an identified GMB-tryptophan metabolite axis.

A Review Article published in 2022 in the journal Chinese Medicine found that Chinese herbal medicine interventions, particularly those based on the Bai-Tou-Weng-Tang and Shen-Ling-Bai-Zhu-San formulas, show promise in treating Ulcerative Colitis. This study analyzed Ulcerative Colitis clinical trials that used Chinese Herbal Medicine (CHM) interventions by systematically searching seven electronic databases for articles published in English and Chinese until November 25, 2020. The focus was on different CHM treatments, including both single herbs and CHM formulas. Descriptive statistics were utilized to portray the characteristics of these studies, along with collecting commonly Chinese Medicine (CM) patterns of UC and frequently used CHM herbs and formulas. The data from a total of 2311 studies were compiled, most of which were Randomized Controlled Trials (RCTs) that utilized CHM formulas. Findings revealed that the most commonly reported CM pattern in UC was 'Large Intestine Dampness-Heat', with 'Spleen Deficiency' being the basic CM pattern-type reported. Top CHM treatment formulas included Bai-Tou-Weng-Tang and Shen-Ling-Bai-Zhu-San. The most frequently used single medicinals were Huang Lian and Bai Zhu. Common Western medicine compounds used in tandem with CHM treatments were Sulfasalazine and Mesalazine.

A Review Article published in 2022 in the journal The American Journal of Chinese Medicine found that Acupuncture shows promising results in managing autoimmune diseases by potentially regulating immune responses. The methodology of the study involved a comprehensive review of how acupuncture, a form of traditional Chinese medicine, may be employed as a treatment method for autoimmune diseases such as multiple sclerosis, rheumatoid arthritis, and inflammatory bowel disease. The research was based on existing knowledge and accumulating data, investigating the role of acupuncture in regulating immune responses during these conditions. The discussion of the results revealed that acupuncture showed promise in managing these diseases. It was noted that the positive outcomes observed might be linked to the potential of acupuncture to regulate abnormal immune responses which are characteristic of autoimmune diseases. Despite the fact that the precise mechanism through which this achieved is not fully understood, the findings indicate a promising alternative method of managing autoimmune conditions.

A Randomised Controlled Trial published in 2022 in the journal EClinicalMedicine found that Acupuncture effectively induced and sustained remission in active Crohn's disease patients, linked to an increase in anti-inflammatory gut bacteria and improved intestinal barrier. In a 48-week randomized, sham controlled, parallel-group clinical trial conducted at a Chinese tertiary outpatient clinic, 66 drug-resistant, mild to moderately active Crohn's disease patients were randomly assigned equally to a control or acupuncture plus moxibustion treatment group. Three treatment sessions were provided weekly for 12 weeks, followed by 36 weeks of follow-up. The acupuncture treatment was significantly more effective than the sham treatment in terms of clinical remission and response rates by week 12, results which were maintained at week 48. The acupuncture group also displayed lower Crohn's disease activity indices and C-reactive protein levels and a decreased recurrence rate. Post-treatment, this group demonstrated an increase in the diversity and relative abundance of intestinal microbiota, particularly anti-inflammatory bacteria, as well as reduced plasma levels of diamine oxidase, lipopolysaccharide, and Th1/Th17 related cytokines.

A Review Article published in 2022 in the journal Evidence-Based Complementary and Alternative Medicine found that Acupuncture can regulate both innate and adaptive immunity of IBD patients, including the balance of Th17/Treg and Th1/Th2 cells, and also modulate intestinal flora. The methodology of the research revolved around a review of existing studies related to the treatment of Inflammatory Bowel Disease (IBD) via acupuncture. The broad scope of exploration focused on the effects of acupuncture on the immunomodulatory mechanism inherent in these patients. The review pursued a detailed study of how acupuncture directly influenced both the innate and adaptive immunity systems in IBD patients as well as its regulation on their intestinal flora. The results discussion revealed that acupuncture had multiple immunomodulatory effects on IBD patients. On one hand, it influenced their innate immunity by regulating elements such as their intestinal epithelial barriers, toll-like receptors, NLRP3 inflammasomes, oxidative stress, and endoplasmic reticulum stress. On the other hand, it affected their adaptive immunity by modulating the balance of Th17/Treg and Th1/Th2 cells. Furthermore, an interesting revelation from the study was that acupuncture could also significantly regulate the intestinal flora of the patients.

A Review Article published in 2022 in the journal Critical Reviews in Food Science and Nutrition found that Goji berries, notably their polysaccharides, exhibit protective effects against inflammatory bowel disease through the preservation of healthy gut microbiota. The review encompassed an in-depth analysis of current literature specially focusing on the role of goji berry and its important functional constituents in countering Inflammatory Bowel Disease (IBD). The core attentiveness of the research is directed towards understanding the interplay between goji berries, particularly their polysaccharides, and gut microbiota. The goji berries’ protective effects were evaluated, focusing on how they curb disruption in gut microbiota, a common facet in IBD. The review concluded that goji berries, especially their polysaccharides, demonstrated appreciable benefits in averting gut microbiota disturbances seen with IBD, thus protecting against this condition. These natural substances, present in goji berries, function as prebiotics, which maintain a balanced gut microbial ecosystem. The research further revealed that proper functioning of gut microbiota and their metabolites was a crucial element in mediating these beneficial effects against IBD, thus cementing the role of dietary interventions in managing diseases linked with gut health.

A Systematic Review published in 2021 in the journal Phytomedicine found that Chinese medicine's unique immune regulation, intestinal flora regulation, and improved intestinal barrier function offer new approaches to managing chronic Inflammatory Bowel Disease. The study involved a comprehensive review of literature from peer-reviewed and clinical databases such as PubMed, Web of Science, ClinicalTrials.gov, MEDLINE, EMBASE, Springer LINK, Wan-fang database, the Chinese Biomedicine Database, and the China National Knowledge Infrastructure. Keywords such as inflammatory bowel disease (including Ulcerative colitis or Crohn's disease) and Chinese medicine were used, focusing on studies conducted between 1997 and 2021, while excluding those that did not meet specific criteria. The review primarily focused on the pathogenesis of IBD and how Chinese medicine plays a role in its treatment, particularly in immune regulation, intestinal flora regulation, and improvement of intestinal barrier function. The collective findings present exciting progress in understanding how multi-herbal Chinese medicine can potentially contribute to the treatment of IBD.

A Systematic Review published in 2021 in the journal Phytomedicine found that Chinese medicine presents unique advantages in managing Inflammatory Bowel Disease (IBD) through immune regulation, intestinal flora regulation, and improvement of intestinal barrier function. In their research, the researchers conducted a systematic review of studies that assessed the effects and mechanics of Chinese medicine in treating IBD. They performed a literature search on various peer-reviewed and clinical databases, including reputable international and Chinese sources. The keywords used for this comprehensive search included "inflammatory bowel disease", "Ulcerative colitis", "Crohn's disease", and "Chinese medicine". Only articles from the period of 1997-2021 that met their exclusion criteria were chosen for the review. The compiled research illuminates recent progression in using Chinese medicine to treat IBD. Certain studies specifically look at how Chinese medicine impacts immune regulation, intestinal flora regulation, and the enhancement of intestinal barrier function in IBD patients. This information could serve as a key reference for further exploration regarding the potential of classical multi-herbal Chinese medicine in treating IBD.

A Meta-Analysis published in 2021 in the journal BMC Complementary Medicine and Therapies found that Traditional Chinese Medicine may potentially be a viable treatment option for ulcerative colitis, but its effectiveness varies depending on the method of administration applied. The authors conducted an extensive electronic literature search across six databases to find systematic reviews about the use of various Chinese medicine therapies for ulcerative colitis. They evaluated the reviews based on the methodology used for assessing their quality. Nine interventions fit the eligibility criteria from the 73 systematic reviews used for the study. It was found that the disease stages of patients with ulcerative colitis ranged greatly and therefore, influenced the outcomes of various treatment approaches. The authors found that the results mostly favored the method of intervention used, with oral administration combined with an enema being the most widely preferred administration route. Notably, many of the reviews didn't report essential factors such as the disease's location, the classification, and the intervention's route of administration. The current evidence indicates that while TCM could be a treatment for UC, it should be applied cautiously due to these inconsistencies.

A Systematic Review published in 2021 in the journal International Journal of Biological Macromolecules found that Polysaccharides from tremella fuciformis can attenuate ulcerative colitis. The purpose of this paper was to explore the therapeutic effect and underlying mechanism of Tremella fuciformis polysaccharides (TFP) on ulcerative colitis (UC) based on dextran sodium sulfate (DSS)-induced mice UC model and lipopolysaccharide (LPS)-stimulated Caco-2 cells model. The results firstly indicated that TFP can significantly alleviate the symptoms and signs of the DSS-induced mice UC model, which manifests as improvement of body weight loss, increase of colon length, decrease of colon thickness and reduction of intestinal permeability. Then, results from histopathological and electron microscope analysis further implied that TFP could dramatically reduce inflammatory cells infiltration and restore intestinal epithelial barrier integrity. In addition, the experiments of LPS-stimulated Caco-2 cells model in vitro also further confirmed that TFP could markedly inhibit the expressions of pro-inflammatory cytokines and increase related genes or proteins expressions of intestinal barrier and mucus barrier. Taken together, these data suggested that TFP has a significant therapeutic effect on DSS-induced UC model, and its mechanisms are closely linked to the inhibition of inflammation and the restoration of intestinal barrier and mucus barrier function. These beneficial effects may make TFP a promising drug to be used in alleviating UC.

A Systematic Review published in 2021 in the journal International Journal of Biological Macromolecules found that Tremella fuciformis polysaccharides effectively reduce inflammation in ulcerative colitis, promoting healing by restoring intestinal and mucus barrier functions. In this study, two models were utilized to investigate the impacts of Tremella fuciformis polysaccharides on ulcerative colitis: a dextran sodium sulfate-induced mice model and a lipopolysaccharide-stimulated model using Caco-2 cells. First, the dextran sodium sulfate-induced mice ulcerative colitis model was administered with the Tremella fuciformis polysaccharides. Effects were observed across several indicators such as body weight, colon length, and thickness, as well as intestinal permeability. Following that, histopathological analysis and electron microscope examinations helped delve deeper into the relationship, uncovering a reduction in inflammatory cell infiltration and a restoration of the intestinal epithelial barrier integrity. The lipopolysaccharide-stimulated Caco-2 cells model was used to further understand the role of these polysaccharides in reducing expressions of pro-inflammatory cytokines and increasing expressions related to intestinal barrier and mucus barrier.

A Review Article published in 2021 in the journal Anesthesiology and Pain Medicine found that Acupuncture is shown to be a beneficial supplementary treatment for chronic abdominal pain, improving patients' quality of life and cutting healthcare costs. The research explores the utilization of acupuncture to treat chronic abdominal pain, a condition widespread and chiefly affected by Irritable Bowel Syndrome (IBS) and Inflammatory Bowel Disease (IBD). This type of pain is defined by three episodes of severe abdominal pain over a span of three months. While its causes are still being looked into, it is believed to be an outcome of the chronicity of acute pain or chronic pain syndromes. A wide array of treatments for these conditions exist but often fall short of fully controlling the symptoms. Acupuncture, a form of traditional Chinese medicine based on the concept of rebalancing the patient's Qi, or Ying/Yang balance, is being investigated as a complementary method. In terms of results, acupuncture has proven effective in providing additional alleviation of symptoms, leading to improved quality of life and reduced disability for patients affected by chronic abdominal pain. While it's not a curative solution, it aids in minimizing symptoms and enhancing overall life quality. It is also considered a safe and inexpensive alternative that may result in significant healthcare savings. Notably, it's not recommended for all patients; its benefits seem to be more pronounced in a select group.

A Review Article published in 2021 in the journal Anesthesiology and Pain Medicine found that Acupuncture has shown promise as a complementary approach in treating chronic abdominal pain, providing symptom relief and improving quality of life. The methodology revolves around applying acupuncture, a form of integrative medicine from traditional Chinese medicine, to patients suffering from chronic abdominal pain. This pain is defined as having three severe abdominal pain instances over three months, often caused by chronic acute pain or chronic pain syndromes, primarily IBS and IBD. Despite existing treatments, these often fail to control the symptoms completely, leaving room for complementary methods like acupuncture. This practice is based on rebalancing a patient's Qi, or Ying/Yang balance, previously shown effective in treating various conditions. The results reveal that acupuncture can serve as a crucial adjunct in managing chronic abdominal pain. It is not a cure, but it significantly aids in symptom reduction and quality of life improvement. Particularly for those affected by IBS and IBD, acupuncture offers extra relief from lingering symptoms, thereby improving quality of life, decreasing disability, and potentially contributing to healthcare cost savings. Acupuncture has emerged as a safe, inexpensive, and beneficial approach for selected patients suffering from chronic abdominal pain.

A Review Article published in 2021 in the journal Pharmacological Research found that Baicalin, a Scutellaria baicalensis extract, has been found to have numerous therapeutic applications in liver and gut diseases by mediating apoptosis and immune response pathways. High-throughput screening and bioinformatics technology were utilized in the extraction and study of baicalin from the dried root of Scutellaria baicalensis Georgi, an herb traditionally used in Chinese medicine. The research sought to understand the biological action of baicalin, particularly how it affects diseases related to the liver and gut. The effects were associated mainly with downstream apoptosis and immune response pathways, which are induced by upstream oxidative stress and inflammation. In the discussion of the resultant findings, it was identified that baicalin engages various key factors during oxidative stress regulation. These include PI3K/Akt/NRF2, Keap-1, NF-κB, and HO-1, contributing to the healing effects of baicalin on non-alcoholic fatty liver disease/non-alcoholic steatohepatitis, ulcerative colitis, and cholestasis. Further, it was discovered that baicalin plays a therapeutic role in regulating inflammatory response and apoptosis pathways. This ability aids in the alleviation of liver diseases and suppression of hepatocellular carcinoma. Baicalin was also found to regulate the intestinal flora by promoting the production of short-chain fatty acids, shedding new light on the full range of baicalin's pharmacological effects.

A Experimental Study published in 2020 in the journal Scientific Reports found that Mu Dan Pi (MDP) and its water extract may serve as potential treatment options for inflammatory bowel disease. In the study, the anti-inflammatory impacts of Mu Dan Pi and its primary active compounds on inflammatory bowel disease were assessed systematically. Screening was done via NF-κB and interferon regulatory factor reporter assays in THP-1 cells, stimulated with particular gene activators. This process was later verified in bone marrow-derived macrophages. The water extract of Mu Dan Pi considerably hindered the activation of NF-κB and IRF reporters, modifying downstream signaling pathways and decreasing the production of IL-6 and TNF-α, based on dosage. In subsequent observations, among the five known active components identified within Mu Dan Pi, one component known as PGG distinguished itself as the most effective at inhibiting reporters and reducing IL-6 and TNF-α. On a clinical application level, both MDP powder and its water extract mitigated colitis and pathological changes in mice, although PGG did not present any significant reduction. This suggests that the anti-inflammatory qualities of Mu Dan Pi may hold therapeutic potential for inflammatory bowel disease.

A Meta-Analysis published in 2019 in the journal Evidence-Based Complementary and Alternative Medicine found that Traditional Chinese Medicine (TCM), when used alongside Western Medicine (WM), seems to improve treatment outcomes for Crohn's disease. The methodology used in this study was a comprehensive search of several significant scientific and medical databases including Pubmed, Embase, Medline, Web of Science, among others, up until October 2018. The researchers assessed the quality of randomized clinical trials that met their specific inclusion criteria and extracted data according to the Cochrane Review Handbook v5.0 guidelines. They analyzed the outcomes using the software Stata 12.0 for a meta-analysis, focusing on twelve selected randomized controlled trials. The trials were, however, deemed of low methodological quality. The study looked at the outcomes of Traditional Chinese and Western Medicine treatment in comparison to Western Medicine alone, across multiple efficacy indicators. This review found that TCM used as an adjunctive therapy to WM was superior to WM alone in inducing remission in Crohn's patients. The results were noticeably better in terms of overall effective rate, maintenance of remission, reduction of C-reactive protein and erythrocyte sedimentation rate, and in reducing clinical scores. Additionally, the frequency of adverse events decreased. Mucosal healing improved in both the TCM-WM and the WM only groups, but no notable differences were present between these two approaches. Still, there was some sign of publication bias in the studies towards efficacy, adverse reactions, mucosal healing, and recurrence rate.

A Practice Guideline published in 2018 in the journal Inflammatory Bowel Diseases found that Acupuncture has been shown to decrease disease activity and inflammation via increase of vagal activity in inflammatory bowel disease. In this review, we discuss the history, theory, and methodology of acupuncture and review potentially beneficial mechanisms of action of acupuncture for managing inflammatory bowel disease. Acupuncture has been shown to decrease disease activity and inflammation via increase of vagal activity in inflammatory bowel disease. Acupuncture has demonstrated beneficial roles in the regulation of gut dysbiosis, intestinal barrier function, visceral hypersensitivity, gut motor dysfunction, depression/anxiety, and pain, all of which are factors that can significantly impact quality of life in patients with inflammatory bowel disease.

A Systematic Review published in 2013 in the journal Evidence-Based Complementary and Alternative Medicine found that Acupuncture and moxibustion therapy show greater effectiveness than oral sulphasalazine in treating inflammatory bowel diseases. For the methodology, seven significant databases, both domestic and international, were meticulously searched to accumulate and examine randomized controlled trials (RCTs). These trials specifically compared acupuncture and moxibustion as the main intervention to pharmacotherapy in treating Inflammatory bowel diseases (IBD). In total, 43 RCTs were incorporated and examined, 10 of which distinctly compared oral sulphasalazine with acupuncture or/and moxibustion treatments. In regards to the results received, the study found that acupuncture and moxibustion therapy displayed superior results when compared with oral sulphasalazine. This conclusion is drawn from the meta-analysis of the 10 trials focusing specifically on these treatments. Even though the systemic review presented several limitations and a definitive conclusion wasn't reached, it still laid groundwork for the potential effectiveness of acupuncture and moxibustion therapy in managing Inflammatory bowel diseases.

Moderation Tools

---

Topic